Switzerland-based Roche (SIX: RO, ROG;OTCQX: RHHBY) has received Emergency Use Authorisation from the United States Food and Drug Administration (FDA) for its Elecsys Anti-SARS-CoV-2 S antibody test, it was reported on Tuesday.
The test can be utilised to measure the level of antibodies in people that have been exposed to the SARS-CoV-2 virus. It is aimed at antibodies that are directed against the region of the novel coronavirus known as the spike protein, specifically the area that allows the virus cell to bind to the host cell receptor, that is required for the virus to enter the host cell. It also offers a numerical result from 0.40-250 U/mL and a qualitative result. It runs on the company's widely available cobas e analysers.
The company is to start shipping the Elecsys Anti-SARS-CoV-2 S test to United States laboratories in the next week. The first lab to provide the testing option in the United States is LabCorp, an early adopter of the test with broad geographic reach.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid